Tanvex BioPharma, Inc. (TPE: 6541)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
67.00
-3.60 (-5.10%)
Sep 13, 2024, 1:30 PM CST

Tanvex BioPharma Balance Sheet

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Cash & Equivalents
910.33380.75786.232,2232,0692,427
Upgrade
Short-Term Investments
130.28-----
Upgrade
Cash & Short-Term Investments
1,041380.75786.232,2232,0692,427
Upgrade
Cash Growth
-14.70%-51.57%-64.63%7.46%-14.78%-31.18%
Upgrade
Accounts Receivable
17.899.40.332.52--
Upgrade
Other Receivables
30.3627.4327.3625.3125.571.29
Upgrade
Receivables
48.2536.8327.6927.8425.571.29
Upgrade
Inventory
106.67108.29170.8490.3350.0852.2
Upgrade
Prepaid Expenses
23.7978.3558.9560.85119.25124.03
Upgrade
Total Current Assets
1,219604.211,0442,4022,2642,605
Upgrade
Property, Plant & Equipment
1,9261,9282,1512,1141,906922.96
Upgrade
Other Intangible Assets
4.753.3812.0710.1711.9615.93
Upgrade
Other Long-Term Assets
237.99227.67213.47187.58190.9829.13
Upgrade
Total Assets
3,3882,7633,4204,7144,3733,573
Upgrade
Accrued Expenses
109.6-115.93137.49210.99179.66
Upgrade
Current Portion of Long-Term Debt
----54.77-
Upgrade
Current Portion of Leases
171.16163.45124.6588.7565.7471.07
Upgrade
Current Unearned Revenue
21.996.9128.07---
Upgrade
Other Current Liabilities
32.5193.3834.6322.2821.619.72
Upgrade
Total Current Liabilities
335.26363.73303.29248.51353.1270.45
Upgrade
Long-Term Debt
----35.53-
Upgrade
Long-Term Leases
1,5671,5681,7151,6701,363271.67
Upgrade
Long-Term Unearned Revenue
8.1410.23----
Upgrade
Other Long-Term Liabilities
--10.47---
Upgrade
Total Liabilities
1,9101,9422,0281,9191,752542.12
Upgrade
Common Stock
1,6401,3403,5273,5253,1162,642
Upgrade
Additional Paid-In Capital
13,55612,43111,06110,9889,6538,348
Upgrade
Retained Earnings
-13,540-12,755-12,969-11,327-9,784-7,680
Upgrade
Comprensive Income & Other
-178.42-194.17-227.09-390.12-364.04-279.38
Upgrade
Shareholders' Equity
1,478821.111,3912,7952,6213,031
Upgrade
Total Liabilities & Equity
3,3882,7633,4204,7144,3733,573
Upgrade
Total Debt
1,7381,7321,8391,7591,519342.74
Upgrade
Net Cash (Debt)
-697.54-1,351-1,053463.95549.192,085
Upgrade
Net Cash Growth
----15.52%-73.66%-40.90%
Upgrade
Net Cash Per Share
-4.98-10.48-8.954.276.1425.45
Upgrade
Filing Date Shares Outstanding
164.03133.96117.64117.57103.9588.13
Upgrade
Total Common Shares Outstanding
164.03133.96117.64117.57103.9588.13
Upgrade
Working Capital
884.06240.48740.432,1531,9102,335
Upgrade
Book Value Per Share
9.016.1311.8323.7725.2134.39
Upgrade
Tangible Book Value
1,473817.731,3792,7852,6093,015
Upgrade
Tangible Book Value Per Share
8.986.1011.7323.6825.1034.21
Upgrade
Machinery
1,053982.54975.18889.53884.87863.48
Upgrade
Construction In Progress
96.3383.7172.8253.848.7849.41
Upgrade
Leasehold Improvements
448.01415.69388.62318.95322.42340.54
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.